ArticleCureus2025
The Role of Encephaloduroarteriosynangiosis in Moyamoya Disease: A Consecutive Case Series From Pakistan.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Moyamoya disease is a rare cerebrovascular disorder characterized by the occlusion of cerebral arteries due to stenosis. Although the disease lacks a specific treatment approach, various surgical options have been discovered to address ischemic issues, including indirect bypass, direct bypass, and their combination, which aim to enhance cerebral blood flow. Indirect revascularization via encephaloduroarteriosynangiosis (EDAS) is deemed effective in preventing additional strokes, although its use for preventing future hemorrhagic stroke in Moyamoya disease remains a subject of controversy. Objective The aim of this study was to evaluate the clinical outcomes of EDAS in hemorrhagic Moyamoya disease. Methodology This retrospective cohort study included eight consecutive patients with hemorrhagic Moyamoya disease who underwent indirect revascularization via EDAS from January 2019 to March 2024 at the Department of Neurosurgery, Punjab Institute of Neurosciences, Lahore, Pakistan. Of these eight patients, one patient was excluded owing to the non-availability of follow-up data. The data were collected in October 2024 by reviewing patient demographics, clinical characteristics, imaging findings, hematological parameters, treatment options, treatment outcomes, and follow-up data from hospital records. Results The mean age of study participants was 14.7±6.8 years. The mean preoperative Glasgow coma scale (GCS) score and the modified Rankin scale (mRS) score were 12.8±2.3 and 2.3±1.4, respectively. Following EDAS, four (57.1%) patients developed collateral circulation with grade A, whereas three (42.8%) patients had grade B according to the Matsushima grading system. The mean postoperative GCS score was 14.0±1.4, whereas the mean postoperative mRS score was 1.3±1.2. Only two patients developed postoperative ischemic symptoms, while none of them developed recurrent intracranial hemorrhage. Conclusion Appreciating the small size of the study, we recommend the effective utilization of EDAS in preventing strokes and improving functional outcomes in patients with hemorrhagic Moyamoya disease. The favorable role of EDAS is justified due to the lack of recurrent intracranial hemorrhage in our patients during the follow-up period.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.